Gammatile
Payments companies reported to CMS as associated with Gammatile. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Gammatile, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Gammatile
These are the largest totals companies reported as associated with Gammatile. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Mccracken | Atlanta, GA | Neurological Surgery | $323,474.01 |
| Imran Mohiuddin | Orlando, FL | Radiation Oncology | $80,356.27 |
| Daniel Kim | Fairfax, VA | Radiation Oncology | $49,293.15 |
| Joseph Zabramski | Phoenix, AZ | Neurological Surgery | $45,701.68 |
| Simon Hanft | Valhalla, NY | Neurological Surgery | $41,952.74 |
| Matthew Shepard | Pittsburgh, PA | Neurological Surgery | $38,807.69 |
| Brandon Imber | New York, NY | Radiation Oncology | $35,925.23 |
| John David | Tampa, FL | Radiation Oncology | $35,406.15 |
| Albert Chang | Los Angeles, CA | Radiation Oncology | $34,070.29 |
| Ken Tatebe | Chicago, IL | Radiation Oncology | $27,319.61 |
Prescribed Gammatile?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.